Influence of Postoperative Treatment on Survival in Patients with Uterine Papillary Serous Carcinoma

Bancher‐Todesca, Dagmar; Neunteufel, W.; Williams, Katherine E.; Prainsack, Doris; Breitenecker, G.; Friedlander, Michael; Hacker, Neville F.

doi:10.1006/gyno.1998.5202

Cited by 43 publications

(29 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Average age of type 2 cancer-affected patients is very high. Bancher-Todesa et al, reported that mean age of patients with UPSC was 72.4 years [8], while Rosenberg et al, reported it to be 69 years [9]. Regardless, mean age of patients in our series was incompatible with the literature.…”

Section: Discussioncontrasting

confidence: 66%

“…Postmenopausal bleeding was identified as the initial symptom in 22 (95.7%) patients from the UPSC and 11 patients (72.7%) with from the CC groups in our study. In a study by Bancher-Todesca et al, postmenopausal bleeding was reported as the initial symptom in 20 out of 23 patients [8]. In our study, obesity, diabetes, and hypertension were not found to be associated with the development of non-endometrioid types of disease.…”

Section: Discussioncontrasting

confidence: 45%

“…Although radiotherapy is a significant adjuvant treatment for endometrioid tumors, the use of adjuvant radiotherapy in non-endometrioid tumors is slightly different [25,26]. Bancher-Todesca et al, reported that mean 5-year survival is 30% in patients with UPSC who were only treated with radiotherapy [8]. On the other hand, Mallipeddi et al, informed about a 50% survival in 10 patients who were treated by total abdominal radiotherapy [27], but Frank et al, reported that that treatment has no benefit [28].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of clinicopathological features, evaluation of treatment, and prognosis of clear cell and serous papillary endometrial carcinoma

Külhan

Kulhan²,

Naykı³

et al. 2016

Ginekol Pol

View full text Add to dashboard Cite

Objectives: We aimed to evaluate and compare the clinical and pathological features, diagnosis, treatment, and prognosis of uterine papillary serous carcinoma (UPSC) and clear-cell carcinoma (CC). Material and methods:Thirty-four patients who were operated on for UPSC and CC carcinoma at the İzmir Tepecik Research and Teaching Hospital, between January 1983 and December 2014, were included. Patients were evaluated for the following factors: age, gravidity, parity, preoperative CA-125, tumor size, myometrial and lymphovascular invasion, lymph node tumor metastasis, presence of atypical cells in peritoneal cytology, pathology results, operation types, whether or not they received postoperative adjuvant therapy, prognosis, and death rate. Results:The stage of the disease was the main factor affecting disease-free and the overall survival. Cisplatin-based chemotherapy was partially effective in patients with postoperative recurrence, while postoperative adjuvant radiotherapy proved to be more effective in preventing relapse. Conclusion:The studied parameters generally were concordant with the literature but, due to the relatively small sample size, more comprehensive and multicenter studies are needed to generate valid results.

show abstract

Section: Discussioncontrasting

confidence: 66%

Section: Discussioncontrasting

confidence: 45%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of clinicopathological features, evaluation of treatment, and prognosis of clear cell and serous papillary endometrial carcinoma

Külhan

Kulhan²,

Naykı³

et al. 2016

Ginekol Pol

View full text Add to dashboard Cite

show abstract

“…The group of patients receiving the combined adjuvant therapy of CT/APRT had a signifi-cantly better 3-year OS (81% compared to 63%) than patients receiving APRT alone (Table 3). This is similar to the results of a previous study that showed 80% 5-year OS for CT and radiotherapy compared to 30% for radiation alone (28) . However, most patients were not surgically staged and thus potentially were ''apparent'' stage I and actually had occult disease in their nodes or upper abdomen.…”

Section: Discussionsupporting

confidence: 91%

Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy

Steed

Manchul

Rosen

et al. 2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

The aim of this study was to compare overall survival (OS), progression-free survival (PFS), and relapse patterns between different modalities of treatment for uterine papillary serous carcinoma (UPSC). A retrospective review of 124 patients with pathologically confirmed UPSC was performed, of whom, 97 patients were eligible for study. Postoperative treatment groups included adjuvant radiotherapy consisting of whole abdomen and a pelvic boost (abdominopelvic radiotherapy [APRT]) (55 patients), paclitaxel and carboplatin chemotherapy (CT) for six cycles followed by APRT (18 patients), CT only (5 patients), and 19 patients were observed without postoperative adjuvant therapy. Three-year OS was 81% and 63% for the CT followed by APRT and APRT alone, respectively (P= 0.11). After controlling for stage, the group treated with APRT alone had significantly decreased OS and PFS compared to the CT/APRT group (HR 3.6; 1.3–9.8; P= 0.01) and (HR 2.9; 95% CI 1.1–7.3; P= 0.03), respectively. Within the limitations of a retrospective study, the results of this study indicate that multimodality postoperative treatment with paclitaxel and a platinum-based CT followed by APRT may increase the survival of patients with UPSC. However, further prospective studies using these combined modalities are needed to confirm these findings.

show abstract

“…Unlike patients with other subtypes of type I endometrial cancer, patients with UPSC are unlikely to be obese, hypertensive or diabetic, or to have a history of hormone replacement therapy, which are typical risk factors for type I endometrial cancer (Hendrickson et al 1982;del Carmen et al 2012). UPSC is an aggressive neoplasm with a high recurrence rate, rapid and deep myometrial invasion, and frequent lymphovascular space involvement (LVSI) (Hendrickson et al 1982;Bancher-Todesca et al 1998). UPSC patients without myometrial invasion also have extrauterine disease, similar to patients with a deeply invasive tumor (Grice et al 1998).…”

Section: Introductionmentioning

confidence: 99%

Decreased Expression of 14-3-3<i>σ</i> Is Predictive of Poor Prognosis for Patients with Human Uterine Papillary Serous Carcinoma

Suzuki

Nagase

Suzuki

et al. 2013

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Uterine papillary serous carcinoma (UPSC) morphologically resembles ovarian serous carcinoma and is categorized as a type II endometrial cancer. UPSC comprises about 10% of all types of endometrial cancer and has an aggressive clinical course and a poor prognosis. The 14-3-3σ gene was originally discovered as a p53-inducible gene; its expression is induced by DNA damage in a p53-dependent manner, which leads to G2 arrest and repair of damaged DNA. Moreover, it has been reported that expression of 14-3-3σ is frequently lost in various types of human cancer, including ovarian cancer. We therefore examined the association between 14-3-3σ expression determined by immunohistochemistry and clinical outcomes of 51 patients with UPSC. UPSC was considered positive for 14-3-3σ when > 30% of tumor cells were stained with a specific antibody. Of these patients, 29 (58.7%) showed positive immunoreactivity for 14-3-3σ and 22 (41.3%) had decreased 14-3-3σ staining. Decreased immunoreactivity for 14-3-3σ was associated with stage (P = 0.001) and lymphovascular space involvement (P = 0.005). Moreover, decreased 14-3-3σ expression was an independent risk factor for reduced overall survival (P = 0.0416) in multivariate analysis. Direct bisulfite sequencing was performed to evaluate the methylation status of the 27 CpG islands in the promoter region and first exon of the 14-3-3σ gene. These CpG islands were hypermethylated in 30% of 14-3-3σ-positive UPSC and 80% of 14-3-3σ-negative UPSC, although the difference was not statistically significant. These findings suggest that decreased expression of immunoreactive 14-3-3σ may be a predictor of poor prognosis in patients with UPSC.

show abstract

Influence of Postoperative Treatment on Survival in Patients with Uterine Papillary Serous Carcinoma

Cited by 43 publications

References 0 publications

Assessment of clinicopathological features, evaluation of treatment, and prognosis of clear cell and serous papillary endometrial carcinoma

Assessment of clinicopathological features, evaluation of treatment, and prognosis of clear cell and serous papillary endometrial carcinoma

Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy

Decreased Expression of 14-3-3<i>σ</i> Is Predictive of Poor Prognosis for Patients with Human Uterine Papillary Serous Carcinoma

Contact Info

Product

Resources

About